Pacira BioSciences Announced Transfer or Voluntary Withdrawal of Listing

Pacira BioSciences (PCRX) notified Nasdaq of its intent to delist shares and deregister under Section 12(b) following its merger with Viatris. The company also plans to terminate registration under Section 12(g) and suspend reporting obligations.

Original reporting
Published Nov 17, 2026, 2:53 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 2:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Pacira BioSciences Announced Transfer or Voluntary Withdrawal of Listing — source image
Decision brief

The 30-second read

$PCRXBearishMed
01

Why it matters

A Nasdaq trading halt plus delisting/deregistration steps can quickly change liquidity, spreads, and eligibility for certain funds, increasing volatility around the filings and any shareholder conversion mechanics.

02

Market read

This is a company-specific corporate status change that can affect tradability immediately and may drive a sharp repricing due to delisting and reporting termination risk.

03

What to watch

Traders should verify whether shareholders receive cash or exchange into Viatris-related consideration, and whether any alternative trading venue exists before assuming permanent liquidity loss.

Relevance 8/10Novelty 8/10Timing: today, after-hours/near-term around the requested Nasdaq trading halt and Form 25 filing

Background

The company says it completed its merger with Viatris and is moving to delist and deregister its shares, including filing Form 25 and intending Form 15 to end Exchange Act reporting.

Company-level read

Ticker impact

$PCRXBearishHigh confidence
Context

Pacira BioSciences notified Nasdaq after completing its merger with Viatris, requesting a trading halt and Form 25 delisting/deregistration.

Expected impact

Likely downside pressure as the market prices reduced liquidity and the path to delisting.

Evidence & confidence

The article describes a direct Nasdaq delisting request (Form 25) and Exchange Act reporting termination intent, which typically increases trading risk and reduces institutional accessibility.

Market effects

Limited spillover, but it highlights heightened delisting risk for small/mid-cap biopharma post-merger structures.

Primarily US market microstructure impact via Nasdaq halt/delisting mechanics.

Low, as the event is US listing and SEC reporting related.

Counterpoint

If the merger structure provides an alternative listing or a clear post-merger trading venue, the delisting may be largely administrative and the stock could stabilize after mechanics settle.

Key entities

  • Pacira BioSciences

    Subject issuer requesting Nasdaq trading halt and Form 25 delisting after merger completion.

  • Viatris

    Counterparty referenced as the merger partner that Pacira says it completed with.

  • Nasdaq

    Exchange notified by Pacira in connection with the requested trading halt and delisting process.

  • SEC

    Pacira references SEC forms (Form 25 and intended Form 15) to delist and terminate reporting.

Related articles

$PCRXMedAI 9/10

Pacira BioSciences, Inc. (PCRX): Completion of Acquisition or Disposition of Assets

Pacira BioSciences, Inc. (PCRX) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 November 17, 2026 To: Holders of Pacira BioSciences, Inc. 2.125% Convertible Senior Notes due 2029 (CUSIP: 695127AJ9) and Computershare Trust Company, National Association as Trustee, Paying Agent and Conversion Agent Corporate Trust Office 1505 Energy Park Drive St.

$VTRSMedAI 8/10

Viatris Completes Acquisition of Pacira BioSciences

Viatris Inc. (VTRS) completed its acquisition of Pacira BioSciences (PCRX) for $36.50 per share. The deal, announced in October, aims to strengthen Viatris's U.S. pain management business. Pacira's shares will be delisted from Nasdaq, and Viatris expects the acquisition to add $90M-$100M in revenue for the rest of 2026.

$PCRXLow

Pacira BioSciences, Inc. (PCRX): RDF has the right to terminate the agreement for an uncured material breach by the Company, in connection with its bankruptcy or insolvency or if it directly…

Pacira BioSciences, Inc. (PCRX) filed an SEC Form 8-K — Regulation FD Disclosure. Item 7.01 Regulation FD Disclosure. As previously disclosed, pursuant to an agreement entered into between the Research Development Foundation (“RDF”) and a wholly-owned subsidiary of Pacira BioSciences, Inc. (the “Company” or “Pacira”), the Company was required to pay RDF a low